Rapamycin Prevents and Breaks the Anti-CD3–Induced Tolerance in NOD Mice

Abstract

Our findings indicate that, when combined with anti-CD3, rapamycin exerts a detrimental effect on the disease outcome in NOD mice for as long as it is administered. These results suggest strong caution with regard to combining these treatments in type 1 diabetic patients.